Rates of Resistant Infections Up in U.S. Children

Share this content:
Rates of Resistant Infections Up in U.S. Children
Rates of Resistant Infections Up in U.S. Children

FRIDAY, Feb. 24, 2017 (HealthDay News) -- Antibiotic-resistant Enterobacteriaceae bacterial infections have increased 700 percent in American children since 2007, according to a study published online Feb. 22 in the Journal of the Pediatric Infectious Diseases Society.

To assess current trends, the study team analyzed data on about 94,000 children under 18 who were treated at one of 48 hospitals nationwide for an Enterobacteriaceae-associated infection between 2007 and 2015.

By 2015, the researchers found that 1.5 percent of these infections were antibiotic-resistant, up from 0.2 percent in 2007. This represented a more than 700 percent increase over eight years, the study authors said. Children with the drug-resistant infections had hospital stays that were 20 percent longer than patients with infections that responded to antibiotics. Most of the resistant infections had developed before the patients went to the hospital for treatment, highlighting increasing community vulnerability.

"While the march of antibiotic resistance seems inexorable, informed and rigorous efforts to reverse this trend have been successful for other types of organisms, and are urgently needed within this context," study author Sharon Meropol, M.D., Ph.D., of the Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine in Cleveland, said in a journal news release.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »